NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00069-1318-04 | 00069-1318 | epoetin alfa-epbx | RETACRIT | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Dec 1, 2020 | In Use | ||
68083-0142-01 | 68083-0142 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/100mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jul 5, 2018 | In Use | ||
55513-0478-01 | 55513-0478 | Epoetin alfa | Epogen | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Mar 3, 1997 | In Use | ||
67157-0111-05 | 67157-0111 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 250.0 mg/mL | Hormonal Therapy | Progestin | Intramuscular | In Use | |||
70771-1374-03 | 70771-1374 | Exemestane | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct 8, 2018 | In Use | ||
70771-1185-03 | 70771-1185 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan 3, 2018 | In Use | ||
50268-0292-11 | 50268-0292 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 30, 2014 | Mar 19, 2018 | No Longer Used | |
00069-1305-10 | 00069-1305 | epoetin alfa-epbx | RETACRIT | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
16729-0035-10 | 16729-0035 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jun 22, 2010 | In Use | ||
59651-0180-90 | 59651-0180 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 11, 2019 | In Use | ||
70518-0920-00 | 70518-0920 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec 22, 2017 | In Use | ||
54868-0290-04 | 54868-0290 | Medroxyprogesterone Acetate | Provera | Hormonal Therapy | Progestin | Oral | Jun 3, 1959 | Jun 30, 2011 | No Longer Used | ||
69097-0909-50 | 69097-0909 | Leuprolide acetate | LEUPROLIDE ACETATE DEPOT | Hormonal Therapy | GnRH Agonist | Jul 15, 2022 | In Use | ||||
00703-3301-04 | 00703-3301 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov 14, 2005 | In Use | ||
52125-0562-08 | 52125-0562 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Feb 28, 2013 | Feb 28, 2014 | No Longer Used | |
59651-0180-30 | 59651-0180 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 11, 2019 | In Use | ||
60429-0910-30 | 60429-0910 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Sep 28, 2016 | Feb 28, 2023 | No Longer Used | |
55513-0148-10 | 55513-0148 | Epoetin alfa | Epogen | 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 16, 1993 | In Use | ||
71731-6121-01 | 71731-6121 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Apr 1, 2021 | In Use | ||
70518-3818-00 | 70518-3818 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug 3, 2023 | In Use | ||
63629-4413-05 | 63629-4413 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Mar 7, 2011 | In Use | ||
00074-3642-03 | 00074-3642 | Leuprolide Acetate | Lupron Depot | Hormonal Therapy | GnRH Agonist | Jan 27, 1989 | In Use | ||||
69448-0023-63 | 69448-0023 | LEUPROLIDE | CAMCEVI | 42.0 mg/.37g | Hormonal Therapy | GnRH Agonist | Subcutaneous | Apr 1, 2025 | In Use | ||
00555-0779-02 | 00555-0779 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Dec 4, 1996 | In Use | ||
55513-0021-01 | 55513-0021 | Darbepoetin alfa | Aranesp | 40.0 ug/.4mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Feb 18, 2011 | In Use |
Found 11564 results — Export these results